文献速递造血干细胞移植与细胞治疗

第三方BK病毒特异性细胞毒T淋巴细胞治疗异基因移植后出血性膀胱炎

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
PubMed 文献 · J Clin Oncol · 2021-04-30

这项临床试验评估了从26名健康供者制备并库存的、与患者HLA最匹配的第三方BK病毒特异性细胞毒T淋巴细胞(BKV-CTLs)治疗异基因造血干细胞移植后BK病毒相关出血性膀胱炎(BKV-HC)的可行性、安全性和疗效。共输注59例患者,第14天总缓解率为67.7%(40/59),第45天升至81.6%(40/49),未发生新发3-4级移植物抗宿主病、移植物失败或输注相关毒性。匹配配对分析显示,校正预后协变量后,BKV-CTLs治疗在所有随访时间点的缓解概率更高,且输血需求显著降低。

要点

  • 第三方BKV-CTLs治疗移植后BKV-HC第14天缓解率67.7%,第45天达81.6%。
  • 未出现新发3-4级GVHD、移植物失败或输注相关毒性。
  • 匹配配对分析显示BKV-CTLs缓解概率更高且输血需求显著降低。

核心结论

  • 现成的第三方BKV-CTLs是治疗异基因造血干细胞移植后BKV-HC安全有效的方法。

研究设计与样本

  • 临床试验(NCT02479698)评估从26名健康供者制备并库存的、与患者HLA最匹配的第三方BKV-CTLs,输注给59例异基因造血干细胞移植后发生BKV-HC的患者。

主要发现

  • 第14天总缓解率为67.7%(40/59可评估患者),第45天在可评估患者中升至81.6%(40/49)。
  • 无患者失去已获得的缓解,未发生新发3级或4级GVHD、移植物失败或输注相关毒性。
  • 输注后3个月内在患者血液中可检测到BKV-CTLs,其体内扩增可预测临床缓解。
  • 匹配配对分析显示,校正预后协变量效应后,与标准治疗相比,BKV-CTLs治疗在所有随访时间点缓解概率更高,且输血需求显著降低。

临床怎么用

  • 对于异基因造血干细胞移植后发生BKV-HC的患者,可考虑使用现成的第三方BKV-CTLs治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor transplants, which are being performed in increasing numbers. BKV-HC typically results in painful hematuria, urinary obstruction, and renal dysfunction, without a definitive therapeutic option. METHODS: We performed a clinical trial (ClinicalTrials.gov identifier: NCT02479698) to assess the feasibility, safety, and efficacy of administering most closely HLA-matched third-party BKV-specific cytotoxic T lymphocytes (CTLs), generated from 26 healthy donors and banked for off-the-shelf use. The cells were infused into 59 patients who developed BKV-HC following AHSCT. Comprehensive clinical assessments and correlative studies were performed. RESULTS: Response to BKV-CTL infusion was rapid; the day 14 overall response rate was 67.7% (40 of 59 evaluable patients), which increased to 81.6% among evaluable patients at day 45 (40 of 49 evaluable patients). No patient lost a previously achieved response. There were no cases of de novo grade 3 or 4 graft-versus-host disease, graft failure, or infusion-related toxicities. BKV-CTLs were identified in patient blood samples up to 3 months postinfusion and their in vivo expansion predicted for clinical response. A matched-pair analysis revealed that, compared with standard of care, after accounting for prognostic covariate effects, treatment with BKV-CTLs resulted in higher probabilities of response at all follow-up timepoints as well as significantly lower transfusion requirement. CONCLUSION: Off-the-shelf BKV-CTLs are a safe and effective therapy for the management of patients with BKV-HC after AHSCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Olson A, Lin R, Marin D, et al. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021. PMID: 33929874. doi:10.1200/JCO.20.02608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。